Back to Agenda
DIAmond Session 1: What Do Patients Want for Clinical Trials and Clinical Research? What Should Stakeholders Do?
Session Chair(s)
Naomi Sakurai
President
CSR-Project, NPO, Japan
Yoshikata Furuya, MSc
Manager, General Affairs Division
Sankeien Hoshoukai Foundation, Japan
Patient and Public Involvement (PPI) in drug developments is increasingly attracting interest in Japan. DIA has organized sessions on PPI at the annual meetings over the past few years to share the concept of PPI and status of PPI in each phase of drug development in Japan and global. In this DIAmond session, leaders of PPI in clinical trials and clinical research will share the latest outcomes and discuss what stakeholders should do to promote PPI in Japan.
Speaker(s)
Yasuhiro Fujiwara, MD, PhD
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Chief Executive
Patients’ expectations in Clinical Trials
Agnès Saint-Raymond, DrMed
European Medicines Agency, Netherlands
Head of Division International Affairs
Promoting Patient and Public Involvement in Japan
Kyoko Imamura, MD, PhD
Graduate School of Pharmaceutical Sciences, the University of Tokyo, Japan
Professor, Social Cooperation Program of IT Healthcare
Patient and Public Involvement (PPI) in drug developments at a pharmaceutical company’s perspective
Takayuki Imaeda, MPharm, MS
Pfizer R&D Japan, Japan
Head of Regulatory Sciences
Have an account?